<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-25</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-25</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>76</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
*   <strong>CSF1RæŠ‘åˆ¶è”åˆåŒ–ç–—å¢å¼ºä¸‰é˜´æ€§ä¹³è…ºç™Œå…ç–«åº”ç­”</strong>ï¼šè¯¥ç–—æ³•é€šè¿‡ç¼“è§£å¸¸é©»è®°å¿†Tç»†èƒåŠŸèƒ½éšœç¢ï¼Œè¯±å¯¼ç³»ç»Ÿæ€§æŠ—è‚¿ç˜¤å…ç–«ï¼Œå¹¶æé«˜è‚¿ç˜¤å¯¹PD-1å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚çš„æ•æ„Ÿæ€§ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«æ²»ç–—</strong>ï¼šç ”ç©¶CSF1RæŠ‘åˆ¶ä¸åŒ–ç–—è”åˆåœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œä¸­çš„å…ç–«å¢å¼ºæœºåˆ¶ï¼Œä»¥åŠ MARCHF8 è›‹ç™½åœ¨è‚¿ç˜¤å…ç–«é€ƒé€¸ä¸­çš„ä½œç”¨ã€‚<br />
*   <strong>é“‚ç±»æŠ—ç™Œè¯ç‰©ä½œç”¨æœºåˆ¶</strong>ï¼šæ¢ç´¢é“‚ç±»æŠ—ç™Œè¯ç‰©ä¸RNAçš„ç›¸äº’ä½œç”¨ï¼Œæ­ç¤ºå…¶è½¬å½•ç»„å­¦å±‚é¢çš„ä½œç”¨æœºåˆ¶ã€‚<br />
*   <strong>åŸºå› ç»„å­¦ä¸è¡¨è§‚é—ä¼ å­¦</strong>ï¼šç ”ç©¶ C9orf72 åŸºå› é‡å¤åºåˆ—RNAé©±åŠ¨çš„è½¬å½•å¤±è°ƒæœºåˆ¶ï¼Œä»¥åŠæ¤ç‰©å…ç–«ä¸­ AtDEK2 çš„ä½œç”¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»´åº¦ç»„å­¦åˆ†æ</strong>ï¼šç»“åˆæ·‹å·´ç»“ã€è‚¿ç˜¤ã€è‚ºã€è¡€æ¶²ç­‰å¤šä¸ªæ ·æœ¬ç±»å‹ï¼Œä»¥åŠ Nanostringã€Luminexã€RNA-seqã€scRNA-seqã€ChIP-seqã€ATAC-seq ç­‰å¤šç§é«˜é€šé‡æµ‹åºæŠ€æœ¯ï¼Œå…¨é¢è§£æè‚¿ç˜¤å¾®ç¯å¢ƒå’Œè¯ç‰©ä½œç”¨æœºåˆ¶ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹è¡€æ¶²æ£€æµ‹å¯æå‰æ•°å¹´é¢„æµ‹é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼›é€šç”¨å‹é¼»å–·ç–«è‹—æœ‰æœ›åŒæ—¶é˜²å¾¡æ–°å† ã€æµæ„ŸåŠè‚ºç‚ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯†åˆ«å¹¶åŒºåˆ†æ–°å† å’ŒHIVæ„ŸæŸ“ä¸­Tç»†èƒçš„å†…åœ¨åŠç³»ç»Ÿæ€§è¡°è€ã€‚<br />
- å·¥ç¨‹èŒé¶å‘è‚¿ç˜¤å†…éƒ¨ï¼Œå®ç°ä½“å†…æ¸…é™¤ã€‚<br />
- æ¢ç´¢æ ¸ç”µç«™é™„è¿‘å±…æ°‘ç™Œç—‡æ­»äº¡ç‡å‡é«˜çš„å…³è”æ€§ã€‚<br />
- é€†è½¬å°é¼ è‚Œè‚‰è¡°è€ï¼Œå‘ç°è›‹ç™½NDRG1è°ƒæ§è‚Œè‚‰ä¿®å¤ä¸ç”Ÿå­˜çš„æƒè¡¡ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åŸºäºå•ç»†èƒè½¬å½•ç»„å­¦çš„Tictockæ—¶é’Ÿï¼Œç²¾ç»†è§£æç»†èƒè¡°è€ã€‚<br />
- åˆ©ç”¨åŸºå› å·¥ç¨‹æ”¹é€ ç»†èŒï¼Œå®ç°è‚¿ç˜¤å†…å®šæ¤å’Œåå™¬ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (70æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE267166 CSF1R æŠ‘åˆ¶å‰‚è”åˆåŒ–ç–—å¯è¯±å¯¼ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œå¹¶é€šè¿‡ç¼“è§£é©»ç•™è®°å¿† T ç»†èƒåŠŸèƒ½éšœç¢ä½¿è‚¿ç˜¤å¯¹ PD-1 æŠ‘åˆ¶å‰‚ç–—æ³•æ›´åŠ æ•æ„Ÿ [æ·‹å·´ç»“]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€lymphã€T cellã€regex:lymph(o|atic)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hope S Rugo ; Amanda Poissonnier ; Eivind V Egeland ; Wesley Horton ; Tiziana Cotechini ; Brian Ruffell ; Cecil Gomes ; Shamilene Sivagnanam ; Nicky Belen ; Dhaarini Murugan ; Nell Kirchberger ; Courtney Betts ; Motomi Mori ; Shivaani Kummar ; K Blackwell ; E Mayer ; Shelley E Hwang ; Lisa M CoussensSeries Type : OtherOrganism : Mus musculusTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive disease where limited therapeutic options are available. A significant correlation exists between presence of intratumoral macrophages, tumor progression, and poor outcomes in TNBC. Preclinical in vivo studies revealed that inhibition of myelomonocytic colony stimulating factor 1 (CSF1) or its receptor (CSF1R), plus cytotoxic therapy decreases primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. To evaluate safety and tolerability of this immune-based therapeutic strategy, we conducted a phase Ib/II clinical trial evaluating Pexidartinib (PLX3397), a small molecule CSF1R inhibitor plus Eribulin chemotherapy in patients with heavily pretreated metastatic TNBC. Correlate analyses from baseline revealed increased leukocyte activation biomarkers, increased presence of CD8+ and CD4+ T central memory cells, and increased PD-1 expression on CD4+ T cells in patients experiencing a partial response or stable disease, together providing evidence of enhanced anti-tumor immunity. We hypothesized that addition of either PD-1 and PD-L1-blockade following CSF1R inhibition and chemotherapy would lead to a further enhanced anti-tumor T cell response. To test this, we evaluated tumor-bearing MMTV-PyMT transgenic mice comparing addition of PD-1- or PD-L1-blockade to Pexidartinib/Paclitaxel therapy. This revealed tumor regression in ~60% of transgenic mice with combined PD-1, but not PD-L1-blockade. Analysis of mammary tumors from mice treated with the PD-1 combination revealed activation and expansion of short-lived effector and memory T cells, and unique clonally-expanded T cells not observed with the PD-L1-blockade combination. These clinical and preclinical findings together provide rationale for addition of CSF1/CSF1R inhibitors to chemotherapy and PD-1-blocakde to further improve outcomes for patients with BC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267166" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE267169 CSF1R æŠ‘åˆ¶å‰‚è”åˆåŒ–ç–—å¯è¯±å¯¼ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œå¹¶é€šè¿‡ç¼“è§£é©»ç•™è®°å¿† T ç»†èƒåŠŸèƒ½éšœç¢ä½¿è‚¿ç˜¤å¯¹ PD-1 æŠ‘åˆ¶å‰‚ç–—æ³•æ›´åŠ æ•æ„Ÿ [nanostring]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hope S Rugo ; Amanda Poissonnier ; Eivind V Egeland ; Wesley Horton ; Tiziana Cotechini ; Brian Ruffell ; Cecil Gomes ; Shamilene Sivagnanam ; Nicky Belen ; Dhaarini Murugan ; Nell Kirchberger ; Courtney Betts ; Motomi Mori ; Shivaani Kummar ; K Blackwell ; E Mayer ; Shelley Hwang ; Lisa CoussensSeries Type : Expression profiling by arrayOrganism : Mus musculusTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive disease where limited therapeutic options are available. A significant correlation exists between presence of intratumoral macrophages, tumor progression, and poor outcomes in TNBC. Preclinical in vivo studies revealed that inhibition of myelomonocytic colony stimulating factor 1 (CSF1) or its receptor (CSF1R), plus cytotoxic therapy decreases primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. To evaluate safety and tolerability of this immune-based therapeutic strategy, we conducted a phase Ib/II clinical trial evaluating Pexidartinib (PLX3397), a small molecule CSF1R inhibitor plus Eribulin chemotherapy in patients with heavily pretreated metastatic TNBC. Correlate analyses from baseline revealed increased leukocyte activation biomarkers, increased presence of CD8+ and CD4+ T central memory cells, and increased PD-1 expression on CD4+ T cells in patients experiencing a partial response or stable disease, together providing evidence of enhanced anti-tumor immunity. We hypothesized that addition of either PD-1 and PD-L1-blockade following CSF1R inhibition and chemotherapy would lead to a further enhanced anti-tumor T cell response. To test this, we evaluated tumor-bearing MMTV-PyMT transgenic mice comparing addition of PD-1- or PD-L1-blockade to Pexidartinib/Paclitaxel therapy. This revealed tumor regression in ~60% of transgenic mice with combined PD-1, but not PD-L1-blockade. Analysis of mammary tumors from mice treated with the PD-1 combination revealed activation and expansion of short-lived effector and memory T cells, and unique clonally-expanded T cells not observed with the PD-L1-blockade combination. These clinical and preclinical findings together provide rationale for addition of CSF1/CSF1R inhibitors to chemotherapy and PD-1-blocakde to further improve outcomes for patients with BC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267169" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE267168 CSF1R æŠ‘åˆ¶å‰‚è”åˆåŒ–ç–—å¯è¯±å¯¼ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œå¹¶é€šè¿‡ç¼“è§£é©»ç•™è®°å¿† T ç»†èƒåŠŸèƒ½éšœç¢ä½¿è‚¿ç˜¤å¯¹ PD-1 æŠ‘åˆ¶å‰‚ç–—æ³•æ›´åŠ æ•æ„Ÿ [luminex]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hope S Rugo ; Amanda Poissonnier ; Eivind V Egeland ; Wesley Horton ; Tiziana Cotechini ; Brian Ruffell ; Cecil Gomes ; Shamilene Sivagnanam ; Nicky Belen ; Dhaarini Murugan ; Nell Kirchberger ; Courtney Betts ; Motomi Mori ; Shivaani Kummar ; K Blackwell ; E Mayer ; Shelley Hwang ; Lisa CoussensSeries Type : Protein profiling by protein arrayOrganism : Homo sapiensTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive disease where limited therapeutic options are available. A significant correlation exists between presence of intratumoral macrophages, tumor progression, and poor outcomes in TNBC. Preclinical in vivo studies revealed that inhibition of myelomonocytic colony stimulating factor 1 (CSF1) or its receptor (CSF1R), plus cytotoxic therapy decreases primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. To evaluate safety and tolerability of this immune-based therapeutic strategy, we conducted a phase Ib/II clinical trial evaluating Pexidartinib (PLX3397), a small molecule CSF1R inhibitor plus Eribulin chemotherapy in patients with heavily pretreated metastatic TNBC. Correlate analyses from baseline revealed increased leukocyte activation biomarkers, increased presence of CD8+ and CD4+ T central memory cells, and increased PD-1 expression on CD4+ T cells in patients experiencing a partial response or stable disease, together providing evidence of enhanced anti-tumor immunity. We hypothesized that addition of either PD-1 and PD-L1-blockade following CSF1R inhibition and chemotherapy would lead to a further enhanced anti-tumor T cell response. To test this, we evaluated tumor-bearing MMTV-PyMT transgenic mice comparing addition of PD-1- or PD-L1-blockade to Pexidartinib/Paclitaxel therapy. This revealed tumor regression in ~60% of transgenic mice with combined PD-1, but not PD-L1-blockade. Analysis of mammary tumors from mice treated with the PD-1 combination revealed activation and expansion of short-lived effector and memory T cells, and unique clonally-expanded T cells not observed with the PD-L1-blockade combination. These clinical and preclinical findings together provide rationale for addition of CSF1/CSF1R inhibitors to chemotherapy and PD-1-blocakde to further improve outcomes for patients with BC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267168" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE267167 CSF1R æŠ‘åˆ¶å‰‚è”åˆåŒ–ç–—å¯è¯±å¯¼ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œå¹¶é€šè¿‡ç¼“è§£é©»ç•™è®°å¿† T ç»†èƒåŠŸèƒ½éšœç¢ä½¿è‚¿ç˜¤å¯¹ PD-1 æŠ‘åˆ¶å‰‚ç–—æ³•æ›´åŠ æ•æ„Ÿ [è‚¿ç˜¤]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hope S Rugo ; Amanda Poissonnier ; Eivind V Egeland ; Wesley Horton ; Tiziana Cotechini ; Brian Ruffell ; Cecil Gomes ; Shamilene Sivagnanam ; Nicky Belen ; Dhaarini Murugan ; Nell Kirchberger ; Courtney Betts ; Motomi Mori ; Shivaani Kummar ; K Blackwell ; E Mayer ; Shelley E Hwang ; Lisa M CoussensSeries Type : OtherOrganism : Mus musculusTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive disease where limited therapeutic options are available. A significant correlation exists between presence of intratumoral macrophages, tumor progression, and poor outcomes in TNBC. Preclinical in vivo studies revealed that inhibition of myelomonocytic colony stimulating factor 1 (CSF1) or its receptor (CSF1R), plus cytotoxic therapy decreases primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. To evaluate safety and tolerability of this immune-based therapeutic strategy, we conducted a phase Ib/II clinical trial evaluating Pexidartinib (PLX3397), a small molecule CSF1R inhibitor plus Eribulin chemotherapy in patients with heavily pretreated metastatic TNBC. Correlate analyses from baseline revealed increased leukocyte activation biomarkers, increased presence of CD8+ and CD4+ T central memory cells, and increased PD-1 expression on CD4+ T cells in patients experiencing a partial response or stable disease, together providing evidence of enhanced anti-tumor immunity. We hypothesized that addition of either PD-1 and PD-L1-blockade following CSF1R inhibition and chemotherapy would lead to a further enhanced anti-tumor T cell response. To test this, we evaluated tumor-bearing MMTV-PyMT transgenic mice comparing addition of PD-1- or PD-L1-blockade to Pexidartinib/Paclitaxel therapy. This revealed tumor regression in ~60% of transgenic mice with combined PD-1, but not PD-L1-blockade. Analysis of mammary tumors from mice treated with the PD-1 combination revealed activation and expansion of short-lived effector and memory T cells, and unique clonally-expanded T cells not observed with the PD-L1-blockade combination. These clinical and preclinical findings together provide rationale for addition of CSF1/CSF1R inhibitors to chemotherapy and PD-1-blocakde to further improve outcomes for patients with BC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267167" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE267165 CSF1R æŠ‘åˆ¶å‰‚è”åˆåŒ–ç–—å¯è¯±å¯¼ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œå¹¶é€šè¿‡ç¼“è§£é©»ç•™è®°å¿† T ç»†èƒåŠŸèƒ½éšœç¢ä½¿è‚¿ç˜¤å¯¹ PD-1 æŠ‘åˆ¶å‰‚ç–—æ³•æ›´åŠ æ•æ„Ÿ [è‚º]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hope S Rugo ; Amanda Poissonnier ; Eivind V Egeland ; Wesley Horton ; Tiziana Cotechini ; Brian Ruffell ; Cecil Gomes ; Shamilene Sivagnanam ; Nicky Belen ; Dhaarini Murugan ; Nell Kirchberger ; Courtney Betts ; Motomi Mori ; Shivaani Kummar ; K Blackwell ; E Mayer ; Shelley E Hwang ; Lisa M CoussensSeries Type : OtherOrganism : Mus musculusTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive disease where limited therapeutic options are available. A significant correlation exists between presence of intratumoral macrophages, tumor progression, and poor outcomes in TNBC. Preclinical in vivo studies revealed that inhibition of myelomonocytic colony stimulating factor 1 (CSF1) or its receptor (CSF1R), plus cytotoxic therapy decreases primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. To evaluate safety and tolerability of this immune-based therapeutic strategy, we conducted a phase Ib/II clinical trial evaluating Pexidartinib (PLX3397), a small molecule CSF1R inhibitor plus Eribulin chemotherapy in patients with heavily pretreated metastatic TNBC. Correlate analyses from baseline revealed increased leukocyte activation biomarkers, increased presence of CD8+ and CD4+ T central memory cells, and increased PD-1 expression on CD4+ T cells in patients experiencing a partial response or stable disease, together providing evidence of enhanced anti-tumor immunity. We hypothesized that addition of either PD-1 and PD-L1-blockade following CSF1R inhibition and chemotherapy would lead to a further enhanced anti-tumor T cell response. To test this, we evaluated tumor-bearing MMTV-PyMT transgenic mice comparing addition of PD-1- or PD-L1-blockade to Pexidartinib/Paclitaxel therapy. This revealed tumor regression in ~60% of transgenic mice with combined PD-1, but not PD-L1-blockade. Analysis of mammary tumors from mice treated with the PD-1 combination revealed activation and expansion of short-lived effector and memory T cells, and unique clonally-expanded T cells not observed with the PD-L1-blockade combination. These clinical and preclinical findings together provide rationale for addition of CSF1/CSF1R inhibitors to chemotherapy and PD-1-blocakde to further improve outcomes for patients with BC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267165" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE267164 CSF1R æŠ‘åˆ¶å‰‚è”åˆåŒ–ç–—å¯è¯±å¯¼ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œå¹¶é€šè¿‡ç¼“è§£é©»ç•™è®°å¿† T ç»†èƒåŠŸèƒ½éšœç¢ä½¿è‚¿ç˜¤å¯¹ PD-1 æŠ‘åˆ¶å‰‚ç–—æ³•æ›´åŠ æ•æ„Ÿ [è¡€æ¶²]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hope S Rugo ; Amanda Poissonnier ; Eivind V Egeland ; Wesley Horton ; Tiziana Cotechini ; Brian Ruffell ; Cecil Gomes ; Shamilene Sivagnanam ; Nicky Belen ; Dhaarini Murugan ; Nell Kirchberger ; Courtney Betts ; Motomi Mori ; Shivaani Kummar ; K Blackwell ; E Mayer ; Shelley E Hwang ; Lisa M CoussensSeries Type : OtherOrganism : Mus musculusTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive disease where limited therapeutic options are available. A significant correlation exists between presence of intratumoral macrophages, tumor progression, and poor outcomes in TNBC. Preclinical in vivo studies revealed that inhibition of myelomonocytic colony stimulating factor 1 (CSF1) or its receptor (CSF1R), plus cytotoxic therapy decreases primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. To evaluate safety and tolerability of this immune-based therapeutic strategy, we conducted a phase Ib/II clinical trial evaluating Pexidartinib (PLX3397), a small molecule CSF1R inhibitor plus Eribulin chemotherapy in patients with heavily pretreated metastatic TNBC. Correlate analyses from baseline revealed increased leukocyte activation biomarkers, increased presence of CD8+ and CD4+ T central memory cells, and increased PD-1 expression on CD4+ T cells in patients experiencing a partial response or stable disease, together providing evidence of enhanced anti-tumor immunity. We hypothesized that addition of either PD-1 and PD-L1-blockade following CSF1R inhibition and chemotherapy would lead to a further enhanced anti-tumor T cell response. To test this, we evaluated tumor-bearing MMTV-PyMT transgenic mice comparing addition of PD-1- or PD-L1-blockade to Pexidartinib/Paclitaxel therapy. This revealed tumor regression in ~60% of transgenic mice with combined PD-1, but not PD-L1-blockade. Analysis of mammary tumors from mice treated with the PD-1 combination revealed activation and expansion of short-lived effector and memory T cells, and unique clonally-expanded T cells not observed with the PD-L1-blockade combination. These clinical and preclinical findings together provide rationale for addition of CSF1/CSF1R inhibitors to chemotherapy and PD-1-blocakde to further improve outcomes for patients with BC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267164" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE294715 The membrane-associated ubiquitin ligase MARCHF8 promotes cancer immune evasion by degrading MHC class I proteins</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€MHC<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mohamed I. Khalil ; Jie Wang ; Canchai Yang ; Lexi Vu ; Smriti Chadha ; Harrison Nabors ; Daniel Vocelle ; Danielle May ; Kyle Roux ; Matthew Bernard ; Qing-Sheng Mi ; Dohun PyeonSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe current immunotherapy is effective, but many cancer patients do not respond. The loss of major histocompatibility complex class I (MHC-I) molecules has been proposed as a mechanism by which cancer cells evade tumor-specific T cells in Immune Checkpoint Inhibitor (ICI)-refractory patients. Nevertheless, how cancer cells downregulate MHC-I is poorly understood. We report here that membrane-associated RING-CH-type finger 8 (MARCHF8), upregulated by human papillomavirus (HPV), ubiquitinates and degrades MHC-I proteins in HPV-positive head and neck cancer (HPV+ HNC). MARCHF8 knockdown restores MHC-I levels on HPV+ HNC cells. We further reveal that Marchf8 knockout significantly suppresses tumor growth and increases the infiltration of natural killer (NK) and T cells in the tumor microenvironment (TME). Furthermore, Marchf8 knockout markedly increases the cytotoxic NK cells and CD8+ T cells and their crosstalk with macrophages and enhances the tumor cell-killing activity of CD8+ T cells. CD8+ T cell depletion in mice abrogates Marchf8 knockout-driven tumor suppression and NK and T cell infiltration. Interestingly, Marchf8 knockout, in combination with anti-PD-1 treatment, synergistically suppresses tumor growth in mice bearing ICI-refractory tumors. Taken together, our finding suggests that MARCHF8 could be a promising target for novel immunotherapy for HPV+ HNC patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294715" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE244561 AtDEK2, a dual histone mark reader regulates plant immunity [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€RNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hanna Alhoraibi ; Santiago Alejandro-Martinez ; David Latrasse ; Papita Mandal ; LÃ©a Faivre ; Deborah Manza ; Xiaoning HE ; Aala A Abulfaraj ; Siba Alharbi ; Kiruthiga Mariappan ; Olga Artyukh ; Fatimah Abdulhakim ; Fatimah Aljedaani ; Stefan David ; Marilia Almeida-Trapp ; Jean Bigeard ; Delphine Pflieger ; Wolfgang Fischle ; Stefan Arold ; Jean Colcombet ; Daniel Schubert ; Moussa Benhamed ; Ikram Blilou ; Heribert Hirt ; Naganand RayapuramSeries Type : Expression profiling by high throughput sequencingOrganism : Arabidopsis thalianaArabidopsis DEK2, a nuclear protein involved in multiple chromatin-related processes, was found to be phosphorylated in response to flg22 treatment suggesting a role in plant immunity to bacterial pathogens. dek2 loss of function mutants were susceptible to bacterial as well as fungal pathogens. Transcriptome data of the dek2-1 mutant shows that AtDEK2 is a transcriptional repressor of defense related genes, hormone synthesis &amp; signaling genes. ChIP-Seq analysis indicates that DEK2 binds to motifs of several families of transcription factors (TFs) and to class I TCP binding motif regions with the highest affinity. We determined that DEK2 is recruited to specific regions on the chromatin by transcription factors. Our data suggests that DEK2 is a reader of the dual histone mark, H3K4me3K27me3. Finally, based on our data we postulate a hypothetical working model for the function of DEK2 as a transcriptional repressor and targets regions with H3K4me3K27me3 marks.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE244561" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE310424 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sreejith Nair ; Arun Krishnaraj ; Richi ThakralSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensClinically used small molecules has been predicted to off-target to RNAs. However, the extend of this interaction is small molecule cancer therapeutics has not been characterized. Here, we screened for anticancer smalll molecules for their RNA interactions and uncovered widespread RNA off-targeting. Cisplatin was found to be one among the RNA binders. We used it as a model agent to identify the specific transcripts it interact with. To accomplish this, we developed Plat-RNAseq, a click-chemistry-mediated transcriptome-wide assay. Our results revealed that cisplatin binding was enriched at guanine-rich regions capable of forming RNA G-quadruplexes (rG4s) .We found that the recruitment of cisplatin to rG4s partially contributed to its cytotoxicity, revealing a noncanonical mechanism of action for this widely used chemotherapeutic agent. RNA seq was performed to catalogue all non-ribosomal RNAs present in A2780 cells.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310424" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE310419 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [Plat-RNAseq cPDS]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNAseqã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sreejith Nair ; Weiyi Guo ; Richi ThakralSeries Type : OtherOrganism : Homo sapiensClinically used small molecules has been predicted to off-target to RNAs. However, the extend of this interaction is small molecule cancer therapeutics has not been characterized. Here, we screened for anticancer smalll molecules for their RNA interactions and uncovered widespread RNA off-targeting. Cisplatin was found to be one among the RNA binders. We used it as a model agent to identify the specific transcripts it interact with. We developed Plat-RNAseq, a click-chemistry-mediated transcriptome-wide assay to map transcriptome-wide interaction of cisplatin. Our results revealed that cisplatin binding was enriched at guanine-rich regions capable of forming RNA G-quadruplexes (rG4s). We use an rG4 ligand, carboxy-Pyridostatin (cPDS), to block access of platin-drug to rG4. This experiment test whether cPDS blocked platinum drug accumulation on cellular RNAs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310419" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 60 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (6æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨6æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>æ–°çš„å•ç»†èƒè½¬å½•ç»„æ—¶é’Ÿæ­ç¤ºäº† COVID-19 å’Œ HIV ä¸­ T ç»†èƒçš„å†…åœ¨å’Œç³»ç»Ÿæ€§è¡°è€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€T cellã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šUsing RNA sequencing at single-cell resolution, researchers developed Tictock to distinguish intrinsic and systemic T cell aging, revealing accelerated immune aging in COVID-19 and...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/new-single-cell-transcriptomic-clock-reveals-intrinsic-and-systemic-t-cell-aging-in-covid-19-and-hiv/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>ç§‘å­¦å®¶æ”¹é€ ç»†èŒï¼Œä½¿å…¶ä»å†…éƒ¨åå™¬ç™Œç»†èƒè‚¿ç˜¤ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€bacteriaã€regex:bacter(ia|ial|ium)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers are engineering bacteria to invade tumors and consume them from the inside. Because tumor cores lack oxygen, theyâ€™re the perfect breeding ground for these microbes. The team added a genetic tweak that helps the bacteria survive longer near oxygen-exposed edges â€” but only once enough of them are present to trigger the change. Itâ€™s a carefully programmed biological attack that could one day offer a new way to destroy cancer.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260224023101.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç®€å•çš„è¡€æ¶²æ£€æµ‹å¯ä»¥åœ¨è®°å¿†ä¸§å¤±å‰æ•°å¹´é¢„æµ‹é˜¿å°”èŒ¨æµ·é»˜ç—…ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have created a blood test that can estimate when Alzheimerâ€™s symptoms are likely to begin. By measuring a protein called p-tau217, the model predicts symptom onset within roughly three to four years. The protein mirrors the silent buildup of amyloid and tau in the brain long before memory loss appears. This advance could speed up preventive drug trials and eventually guide personalized care.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260222085203.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç§‘å­¦å®¶ç ”å‘å‡ºä¸€ç§é€šç”¨é¼»å–·ç–«è‹—ï¼Œå¯é¢„é˜²æ–°å† ç—…æ¯’ã€æµæ„Ÿå’Œè‚ºç‚ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼švaccine<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists at Stanford Medicine have unveiled a bold new kind of â€œuniversalâ€ vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common allergens. Instead of targeting a specific virus or bacterium, the nasal spray vaccine supercharges the lungsâ€™ own immune defenses, keeping them on high alert for months. In mice, it slashed viral levels, prevented severe illness, and even blocked allergic reactions.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260222092258.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>ç¾å›½ä¸€é¡¹å¤§å‹ç ”ç©¶å‘ç°ï¼Œæ ¸ç”µç«™é™„è¿‘ç™Œç—‡æ­»äº¡ç‡è¾ƒé«˜ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA sweeping nationwide study has found that U.S. counties located closer to operating nuclear power plants have higher cancer death rates than those farther away. Researchers analyzed data from every nuclear facility and all U.S. counties between 2000 and 2018, adjusting for income, education, smoking, obesity, environmental conditions, and access to health care. Even after accounting for those factors, cancer mortality was higher in communities nearer to nuclear plants, particularly among older adults.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260224015537.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>ç§‘å­¦å®¶é€†è½¬äº†å°é¼ çš„è‚Œè‚‰è¡°è€ï¼Œå¹¶å‘ç°äº†ä¸€ä¸ªä»¤äººæƒŠè®¶çš„ç°è±¡ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šaging<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA UCLA study in mice reveals that aging muscle stem cells accumulate a protein that slows repair but boosts survival. This protein, NDRG1, acts like a brake, preventing cells from activating quickly after injury. When researchers blocked it in older mice, muscle healing sped up dramatically â€” but stem cells became less resilient over time. The work suggests aging may reflect a survival trade-off rather than straightforward decline.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260222092306.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>21</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>16</td>
</tr>
<tr>
<td>transcriptome</td>
<td>15</td>
</tr>
<tr>
<td>immune</td>
<td>11</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>8</td>
</tr>
<tr>
<td>tumor</td>
<td>8</td>
</tr>
<tr>
<td>genome</td>
<td>8</td>
</tr>
<tr>
<td>T cell</td>
<td>7</td>
</tr>
<tr>
<td>immunity</td>
<td>4</td>
</tr>
<tr>
<td>scRNA</td>
<td>4</td>
</tr>
<tr>
<td>aging</td>
<td>3</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>histone</td>
<td>3</td>
</tr>
<tr>
<td>RNAseq</td>
<td>3</td>
</tr>
<tr>
<td>sequencing</td>
<td>3</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>resistance</td>
<td>1</td>
</tr>
<tr>
<td>macrophage</td>
<td>1</td>
</tr>
<tr>
<td>MHC</td>
<td>1</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (60æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310416" target="_blank" rel="noopener noreferrer">GSE310416 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [Plat-RNAseq A549]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309934" target="_blank" rel="noopener noreferrer">GSE309934 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309812" target="_blank" rel="noopener noreferrer">GSE309812 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [Plat-RNAseq A2780]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314812" target="_blank" rel="noopener noreferrer">GSE314812 å…‹éš†æ¼”åŒ–åˆ†æ­§å’Œè‚¿ç˜¤å¾®ç¯å¢ƒé‡å¡‘å¡‘é€ èƒƒç™Œè…¹è†œè½¬ç§»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320007" target="_blank" rel="noopener noreferrer">GSE320007 æº¶ç˜¤ç—…æ¯’ç–—æ³•å’Œé“‚ç±»åŒ–ç–—ååŒä½œç”¨ï¼Œé€šè¿‡é¶å‘æ¿€æ´»åŒ–ç–—æŒç»­å­˜åœ¨çš„æ—è§‚è€… CD8+ T ç»†èƒæ¥å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«åŠ› [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300820" target="_blank" rel="noopener noreferrer">GSE300820 ç¾Šç»’ç”Ÿé•¿è¿‡ç¨‹ä¸­æ¬¡çº§æ¯›å›Šå¹²ç»†èƒçš„å…¨åŸºå› ç»„ç»„è›‹ç™½ä¿®é¥° [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320254" target="_blank" rel="noopener noreferrer">GSE320254 é¶å‘ RNase H2ï¼šä¸€ç§æé«˜ä¸‰é˜´æ€§ä¹³è…ºç™Œå¤åˆ¶å‹åŠ›ã€DNA æŸä¼¤å’ŒæŠ—è‚¿ç˜¤å…ç–«çš„åŒé‡æœºåˆ¶ç­–ç•¥</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310425" target="_blank" rel="noopener noreferrer">GSE310425 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310421" target="_blank" rel="noopener noreferrer">GSE310421 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [CUT&amp;TAG]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310413" target="_blank" rel="noopener noreferrer">GSE310413 å…¨è½¬å½•ç»„å›¾è°±æ­ç¤ºé“‚ç±»æŠ—ç™Œè¯ç‰©çš„ RNA ä¾èµ–æ€§æœºåˆ¶ [RIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290685" target="_blank" rel="noopener noreferrer">GSE290685 å¯¹ä»å°é¼ è„¾è„ä¸­åˆ†ç¦»çš„ PDXï¼ˆæ‚£è€…æ¥æºçš„å¼‚ç§ç§»æ¤ï¼‰è‚¿ç˜¤è¿›è¡Œå•ç»†èƒ RNA æµ‹åºåˆ†æï¼Œè¿™äº›è‚¿ç˜¤åˆ†åˆ«ç”¨ç©ºè½½ CARã€æŠ— CD72 H24 nanoCAR æˆ–æŠ— CD72 NbD4.13 nanoCAR æ²»ç–—ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290380" target="_blank" rel="noopener noreferrer">GSE290380 RNA-seq åˆ†æï¼šå¸ƒé‡Œå¥¥æ–¯ä»–æ±€æ²»ç–—åäºº SC1 æ·‹å·´ç˜¤ç»†èƒç³»çš„å˜åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310931" target="_blank" rel="noopener noreferrer">GSE310931 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310928" target="_blank" rel="noopener noreferrer">GSE310928 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310926" target="_blank" rel="noopener noreferrer">GSE310926 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310849" target="_blank" rel="noopener noreferrer">GSE310849 è€å¹´å¤§é¼ éª¨éª¼è‚Œåå¤åºŸç”¨æ€§èç¼©ï¼ˆRNA-seq / è½¬å½•ç»„ï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310344" target="_blank" rel="noopener noreferrer">GSE310344 æˆäººéª¨éª¼è‚Œåå¤åºŸç”¨æ€§èç¼©ï¼ˆRNA-seq / è½¬å½•ç»„ï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300821" target="_blank" rel="noopener noreferrer">GSE300821 ç¾Šç»’ç”Ÿé•¿è¿‡ç¨‹ä¸­æ¬¡çº§æ¯›å›Šå¹²ç»†èƒçš„è½¬å½•ç»„åˆ†æ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290340" target="_blank" rel="noopener noreferrer">GSE290340 dsRNA ç—…æ¯’çš„ç—…æ¯’è½¬å½•è°ƒèŠ‚å› å­é€šè¿‡æ“çºµå®¿ä¸»å…±è½¬å½•å› å­ DHX9 æ¥æ‹®æŠ—å…ˆå¤©å…ç–«ååº” [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290339" target="_blank" rel="noopener noreferrer">GSE290339 dsRNA ç—…æ¯’çš„ç—…æ¯’è½¬å½•è°ƒèŠ‚å› å­é€šè¿‡æ“çºµå®¿ä¸»å…±è½¬å½•å› å­ DHX9 æ¥æ‹®æŠ—å…ˆå¤©å…ç–«ååº” [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290327" target="_blank" rel="noopener noreferrer">GSE290327 RNA-seq åˆ†ææ™šæœŸå°¿è·¯ä¸Šçš®ç™Œå¯¹é¡ºé“‚å’Œå‰è¥¿ä»–æ»¨åŒ–ç–—çš„ååº”ï¼šå¤–éƒ¨éªŒè¯é˜Ÿåˆ—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288223" target="_blank" rel="noopener noreferrer">GSE288223 æ•´åˆè½¨è¿¹æ¨æ–­å’Œè‡ªè§£é‡Šé¢„æµ‹æ¨¡å‹ï¼Œä»¥å•ç»†èƒåˆ†è¾¨ç‡æ¢ç´¢ä¹³è…ºç™Œç»†èƒçŠ¶æ€è½¬å˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271982" target="_blank" rel="noopener noreferrer">GSE271982 ç»„è›‹ç™½ä¹™é…°åŒ–ä¾èµ–çš„BRD2èšé›†æŒ‡å¯¼è½¬å½•åŠ¨åŠ›å­¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320213" target="_blank" rel="noopener noreferrer">GSE320213 æ­ç¤º linc00645ï¼šä¸€ç§ Wnt è°ƒæ§çš„ lncRNA é€šè¿‡ linc00645/miR-452-5p/æ³¢å½¢è›‹ç™½è½´é©±åŠ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„ä¸Šçš®-é—´è´¨è½¬åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309448" target="_blank" rel="noopener noreferrer">GSE309448 å°åº¦åŒ»é™¢ä¸­æ°Ÿåº·å”‘è€è¯æ€§çƒ­å¸¦å¿µç èŒçš„å¤šå› ç´ å”‘ç±»è€è¯æ€§ã€å¹¿æ³›å‡ºç°å’Œå…‹éš†ä¼ æ’­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299614" target="_blank" rel="noopener noreferrer">GSE299614 CBP-IDRs è°ƒæ§ä¹™é…°åŒ–å’ŒåŸºå› è¡¨è¾¾ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296518" target="_blank" rel="noopener noreferrer">GSE296518 Prevotella intermedia culture supernatant impairs alveolar macrophage function and promotes Mycobacterium avium persistence</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281802" target="_blank" rel="noopener noreferrer">GSE281802 The metabolic signature of inflammatory skin-imprinted eosinophils accounts for the chronicity of Leishmania mexicana infections [Day50]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281715" target="_blank" rel="noopener noreferrer">GSE281715 The metabolic signature of inflammatory skin-imprinted eosinophils accounts for the chronicity of Leishmania mexicana infections [Day14]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280638" target="_blank" rel="noopener noreferrer">GSE280638 Polycomb Repressive Complex 1 Primes Non-Growing Oocytes for Growth and Early Embryogenesis [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274186" target="_blank" rel="noopener noreferrer">GSE274186 Maternal antibodies orchestrate the establishment of salivary and oral mucosal immunity</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268266" target="_blank" rel="noopener noreferrer">GSE268266 CBP-IDRs regulate acetylation and gene expression [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240512" target="_blank" rel="noopener noreferrer">GSE240512 Profiling of MCM2 and phosphorylated MCM2 in MLL3/4 double mutant and control ESCs [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213213" target="_blank" rel="noopener noreferrer">GSE213213 Human pluripotent stem cellâ€“derived A10 dopaminergic neurons specifically integrate into host circuits and relieve depression [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315332" target="_blank" rel="noopener noreferrer">GSE315332 æ»‹å…»å±‚å¹²ç»†èƒå®šå‘åˆ†åŒ–ä¸ºç‰›èƒç›˜å‘è‚²çš„æœ‰ç”¨ä½“å¤–æ¨¡å‹ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314723" target="_blank" rel="noopener noreferrer">GSE314723 æ»‹å…»å±‚å¹²ç»†èƒå®šå‘åˆ†åŒ–ä¸ºç‰›èƒç›˜å‘è‚²çš„æœ‰ç”¨ä½“å¤–æ¨¡å‹ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309225" target="_blank" rel="noopener noreferrer">GSE309225 LMO2-LDB1-TAL1å¤åˆç‰©è°ƒæ§AMLä¸­çš„è½¬å½•ç½‘ç»œ[ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292624" target="_blank" rel="noopener noreferrer">GSE292624 åˆ†ç¦»çš„äººç±»è„‘ç±»å™¨å®˜åœ¨å¾®ç”µæé˜µåˆ—ä¸Šå‘è‚²å½¢æˆç¥ç»å…ƒç½‘ç»œ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267255" target="_blank" rel="noopener noreferrer">GSE267255 åˆ©ç”¨å•ç»†èƒå¤šç»„å­¦å¯¹äººç±» cDC2 ç¨³æ€æˆç†Ÿç¨‹åºè¿›è¡Œå¤šç»´åº¦è¡¨å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267253" target="_blank" rel="noopener noreferrer">GSE267253 é€šè¿‡å•ç»†èƒRNAæµ‹åºé‰´å®šäººç±»cDC2ç¨³æ€æˆç†Ÿç¨‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262835" target="_blank" rel="noopener noreferrer">GSE262835 æ–°é²œè¡€å°æ¿åˆ†ç¦»æœ¯äººè¡€å°æ¿å’Œå†»å¹²è¡€å°æ¿ï¼ˆè¡€æ “å°ä½“ï¼‰çš„ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115819" target="_blank" rel="noopener noreferrer">GSE115819 IL2Raä¾èµ–æ€§Bç»†èƒå—ä½“åŠå…¶è‡´ç™Œæ¨¡æ‹Ÿç‰©çš„åé¦ˆæ§åˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320238" target="_blank" rel="noopener noreferrer">GSE320238 è‡´å‘½æ€§ç»“æ ¸åˆ†ææ†èŒæ’­æ•£å‘ç”Ÿåœ¨æ·‹å·´ç»†èƒç¼ºå¤±çš„æƒ…å†µä¸‹ï¼Œä¸”ä¸å…ˆå¤©å…ç–«ååº”æ— å…³</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314843" target="_blank" rel="noopener noreferrer">GSE314843 é›„æ€§å°é¼ æ¡ä»¶æ€§ Phf2 æ•²é™¤è…“è‚ è‚Œéª¨éª¼è‚Œè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293503" target="_blank" rel="noopener noreferrer">GSE293503 å¹´è½»é‡ç”Ÿå‹å’ŒKlotho KOé›„æ€§å°é¼ è‚¾è„å’Œè„‘ç»„ç»‡æ ·æœ¬çš„å•æ ¸RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292885" target="_blank" rel="noopener noreferrer">GSE292885 è½¬å½•ç»„å­¦ç‰¹å¾æ­ç¤ºäº†è¡°è€ã€æ…¢æ€§ç–¾ç—…å’Œè¿”è€è¿˜ç«¥çš„æ™®éå’Œç‰¹å¼‚æ€§æœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292884" target="_blank" rel="noopener noreferrer">æ¥è‡ª ITP ç ”ç©¶çš„æš´éœ²äºå„ç§åŒ–åˆç‰©çš„ UM-HET3 å°é¼ è‚è„æ ·æœ¬çš„ GSE292884 RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292843" target="_blank" rel="noopener noreferrer">GSE292843 é‡ç”Ÿå‹å’ŒKlothoåŸºå› æ•²é™¤é›„æ€§å°é¼ è‚¾è„å’Œéª¨éª¼è‚Œæ ·æœ¬çš„RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290665" target="_blank" rel="noopener noreferrer">GSE290665 é›„æ€§å°é¼ æ¡ä»¶æ€§ Phf2 æ•²é™¤è…“è‚ è‚Œéª¨éª¼è‚Œè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290611" target="_blank" rel="noopener noreferrer">GSE290611ï¼šé›„æ€§å°é¼ æ¡ä»¶æ€§Phf2æ•²é™¤å°é¼ è…“è‚ è‚Œå’Œæ¯”ç›®é±¼è‚Œçš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE239775" target="_blank" rel="noopener noreferrer">GSE239775 é€šè¿‡åŸºå› è¯„åˆ†é‡åŒ–å…¨èº«ç‚ç—‡æ­ç¤ºæ€¥æ€§å¤±ä»£å¿æœŸè‚ç¡¬åŒ–çš„ç›¸å…³ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320035" target="_blank" rel="noopener noreferrer">GSE320035 RNA-seq åˆ†æç§€ä¸½éšæ†çº¿è™«æ¶²ä½“è¯±å¯¼ä¼‘çœ ï¼ˆLISAï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319827" target="_blank" rel="noopener noreferrer">GSE319827 é©¯åŒ–äºŒç²’å°éº¦ï¼ˆTriticum turgidum subsp. dicoccumï¼‰å¯¹å°éº¦é¢–æ¯ç—…èŒï¼ˆZymosptoria triticiï¼‰å’Œç¦¾æŸ„é”ˆèŒï¼ˆPuccinia graminisï¼‰å•ä¸€æ„ŸæŸ“ä¸æ··åˆæ„ŸæŸ“ååº”çš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319822" target="_blank" rel="noopener noreferrer">GSE319822 RNA-seq åˆ†æå°é¼ è„Šé«“æŒ«ä¼¤åç»ä¸é¦™ç´ æ²»ç–—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310939" target="_blank" rel="noopener noreferrer">GSE310939 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [ChIRP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310934" target="_blank" rel="noopener noreferrer">GSE310934 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [DRIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310932" target="_blank" rel="noopener noreferrer">GSE310932 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [MeDIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310930" target="_blank" rel="noopener noreferrer">GSE310930 C9orf72 å…­æ ¸è‹·é…¸é‡å¤ RNA é€šè¿‡å…¨åŸºå› ç»„æ··åˆ G-å››é“¾ä½“é©±åŠ¨è½¬å½•å¤±è°ƒ [RAP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310004" target="_blank" rel="noopener noreferrer">GSE310004 æ¥è‡ªåŒé“¾RNAç—…æ¯’çš„ç—…æ¯’è½¬å½•è°ƒèŠ‚å› å­é€šè¿‡æ“çºµå®¿ä¸»å…±è½¬å½•å› å­DHX9æ¥æ‹®æŠ—å…ˆå¤©å…ç–«ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275136" target="_blank" rel="noopener noreferrer">GSE275136 ERVè¡ç”ŸRNA-DNAæ‚äº¤ä½“ä¸Šè°ƒC4bè¯±å¯¼è‡ªé—­ç—‡å°èƒ¶è´¨ç»†èƒçªè§¦ä¿®å‰ª[ChIP-seq]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-24 21:55</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>